公开(公告)号：US20160030405A1

公开(公告)日：2016-02-04

申请号：US14813658

申请日：2015-07-30

申请人： CANCER RESEARCH TECHNOLOGY LIMITED ,  INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)

发明人： Caroline SPRINGER ,  Ion NICULESCU-DUVAZ ,  Richard MARAIS ,  Dan NICULESCU-DUVAZ ,  Alfonso ZAMBON ,  Delphine MENARD

IPC分类号： A61K31/437

CPC分类号： A61K31/437 ,  A61K31/4353 ,  C07D401/02 ,  C07D471/04

摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.

摘要翻译： 本发明一般涉及治疗化合物领域，更具体地涉及下列化学式的某些化合物（为方便起见，统称为“IP化合物”），其特别可用于治疗癌症， 例如以突变RAS（“突变RAS癌”）为特征的癌症（例如，驱动）。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗癌症中的用途，例如突变RAS癌症。

公开(公告)号：US20140357663A1

公开(公告)日：2014-12-04

申请号：US14331653

申请日：2014-08-21

申请人： CANCER RESEARCH TECHNOLOGY LIMITED ,  INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE)

发明人： Caroline SPRINGER ,  Ion NICULESCU-DUVAZ ,  Richard MARAIS ,  Dan NICULESCU-DUVAZ ,  Alfonso ZAMBON ,  Delphine MENARD

IPC分类号： C07D471/04

CPC分类号： A61K31/437 ,  A61K31/4353 ,  C07D401/02 ,  C07D471/04

摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.

摘要翻译： 本发明一般涉及治疗化合物领域，更具体地涉及下列化学式的某些化合物（为方便起见，统称为“IP化合物”），其特别可用于治疗癌症， 例如以突变RAS（“突变RAS癌”）为特征的癌症（例如，驱动）。 本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗癌症中的用途，例如突变RAS癌症。

公开(公告)号：US20240174634A1

公开(公告)日：2024-05-30

申请号：US18265063

申请日：2021-12-10

申请人： Cancer Research Technology Limited

发明人： Christopher Stephen KERSHAW ,  Mohammed ALJARAH ,  Dan NICULESCU-DUVAZ ,  Mark Philip DODSWORTH ,  Cinzia BORDONI ,  Caroline SPRINGER

IPC分类号： C07D401/12 ,  A61P35/00 ,  C07D215/227 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

CPC分类号： C07D401/12 ,  A61P35/00 ,  C07D215/227 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

摘要： The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain aldehyde dehydrogenase inhibitor compounds (also referred to herein as “ALDHI compounds”), that, inter alia, inhibit aldehyde dehydrogenase enzyme ALDH1A3. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit ALDH1A3 enzyme; to treat disorder (e.g., diseases) that are ameliorated by the inhibition of ALDHIA3 enzyme; to treat a proliferative disorder, cancer, obesity, diabetes, a cardiovascular disorder, etc.